11 research outputs found
Effective palliative radiotherapy in primary malignant melanoma of the esophagus: a case report
Unprecedented stereochemical control in the Claisen rearrangement of allyl vinyl ethers using organoaluminum reagents
Preliminary Results of Radiation Therapy for Locally Advanced or Recurrent Adenoid Cystic Carcinomas of the Head and Neck using Combined Conventional Radiation Therapy and Hypofractionated Inverse Planned Stereotactic Radiation Therapy
Prediction of Local Failures with a Combination of Pretreatment Tumor Volume and Apparent Diffusion Coefficient in Patients Treated with Definitive Radiotherapy for Hypopharyngeal or Oropharyngeal Squamous Cell Carcinoma
Design and Synthesis of the Potent, Orally Available, Brain-Penetrable Arylpyrazole Class of Neuropeptide Y5 Receptor Antagonists
A New Class of Highly Potent Farnesyl Diphosphate-Competitive Inhibitors of Farnesyltransferase
T2NO声門癌に対する化学放射線療法, 補助化学療法の遡及的検討
This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy). The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients. Twenty-four patients received adjuvant chemotherapy with tegafur and uracil. Initial local tumor control was achieved in 30 patients (94%). The 5-year overall survival and 5-year local control rates were 97% and 70%, respectively. Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038). The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82% and 42%, respectively. No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis. With regard to adverse reactions, grade 3 neutropenia and grade 3 hepatotoxicity were observed in 1 and 2 patients, respectively. We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy. Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control. We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.目的:T2N0声門癌に対する化学放射線療法,補助化学療法の効果,有害事象の遡及的検討.対象・方法:1993年5月から2004年3月に喉頭温存を目的に初回治療として化学放射線療法を施行されたT2N0声門癌の32例.放射線治療は1日1回,1回2Gy,週5回施行され,総線量の中央値は70Gy.化学療法はカルボプラチン単独が4例,カルボプラチンとUFT の併用が7例,カルボプラチンとフトラフールの併用が2例,フトラフール単独が19 例.化学放射線療法終了後24 例にUFTによる補助化学療法を施行.結果:一次治療効果でCRであったのは30例(94%).5年粗生存率,5年局所制御率はそれぞれ97%,70%.局所制御に関する単変量解析では,補助化学療法の施行により有意な改善を認めた(P=0.038).5年局所制御率は補助化学療法の有無でそれぞれ,82%,42%.総治療期間,総線量,年齢,病変の声門下への進展の有無では有意差は認めなかった.有害事象に関してはgrade3 の好中球減少を1例,grade3の肝機能障害を2例に認めた.重篤な晩期有害事象は認めなかった.結論:T2N0 声門癌に対する補助化学療法は局所制御に関して統計学的に有意な改善が認められ,また有害事象は軽度であり,有用性が示唆された
High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer
局所進行性あるいは再発性の頭頚部腺様囊胞癌に対する通常分割照射+インバースプランによる低分割定位照射追加の治療成績
Purpose. To investigate the clinical outcomes and feasibility of combined conventional radiation therapy (RT) and hypofractionated inverse planned stereotactic radiation therapy (SRT) for locally advanced or recurrent adenoid cystic carcinomas (ACCs) of the head and neck. Patients and methods. Five patients with ACCs of the head and neck were treated with combined conventional RT and inverse planned SRT. Radiation doses of 40 to 50 Gy were delivered with 20 to 25 fractions using conventional RT, and then an additional 20 to 25 Gy was delivered by 4 to 5 fractions of SRT. Results. Median follow-up was 12 months. Local control was obtained in all 5 patients, PR in 2 patients and SD in 3 patients. According to the Radiation Therapy Oncology Group (RTOG) late-radiation morbidity scoring criteria, adverse effects included Grade 2 xerostomia in 1 patient, Grade 2 trismus in 1 patient, and Grade 4 mucosal ulceration in 1 patient. Conclusion. Combined treatment with conventional RT and hypofractionated inverse planned SRT may be effective for short-term local control in patients with locally advanced or recurrent ACCs. Further evaluation is needed for long-term follow-up.目的放射線抵抗性である頭頚部領域の腺様.胞癌に対する通常分割照射+サイバーナイフによるインバースプラン低分割定位照射追加の治療成績を検討する.対象と方法九州大学病院放射線科にて2006 年12 月から2007 年9月までに放射線治療を施行した頭頚部領域の腺様.胞癌5例を対象とした.平均年齢61.4 歳(53-73 歳),男性2例,女性3例,部位は上顎洞2例,中咽頭2例,耳下腺1例で,初発2例,再発3例であった.放射線治療通常分割照射を先行後,腫瘍遺残部にサイバーナイフによる低分割定位照射を追加した.通常分割照射線量は40-50Gy(20-25分割),低分割定位照射追加線量は20-25Gy(4-5分割)で,総線量はα/β=10としてBiological effective doseは78.0.97.5Gy(86.4± 6.3)であった.観察期間中央値は12ケ月(8.18 ケ月)であった.結果腫瘍縮小は全例にみられ,局所制御は100%であった(PR2例,SD3例).1例で照射野外に再発を認め追加放射線治療が施行され,肺・肝転移の1 例は放射線治療後に全身化学療法が施行された.有害事象はRTOGGrade 2 の唾液分泌障害1例,Grade 2の顎関節症1例,Grade 4の粘膜潰瘍を認めた.考察放射線抵抗性腫瘍である腺様.胞癌に対する放射線治療は,通常分割照射のみでは局所制御が充分に得られない可能性があるが,本報告ではサイバーナイフによる低分割定位照射の併用により良好な局所一次効果が確認され,有害事象も許容できると考えられた.今後は長期の腫瘍制御および晩期有害事象の評価が必要と考えられた